---
document_datetime: 2025-11-18 11:44:21
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/omlyclo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: omlyclo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4630794
conversion_datetime: 2025-12-23 06:56:40.135761
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Omlyclo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                                      | Scope                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Extension of marketing authorisation / EMA/X/0000248400 | 2. Changes to strength, pharmaceutical form and route of administration - (c) change or addition of a new strength/potency - Accepted | 18/09/2025                          | 10/11/2025                                  | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000285988   | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in- process limits - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted   | 09/09/2025   | N/A   |                        |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------------------------|
| Variation type IB / EMA/VR/0000285784   | This was an application for a group of variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted                                                                   | 29/07/2025   |       | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted   |            |     |    |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IB / EMA/VR/0000261042 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                          | 10/04/2025 | N/A |    |
| Article 61(3) / EMA/N/0000246792      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                                                                                                                                                                                                    | 26/02/2025 |     | PL |
| Variation type IB / EMA/VR/0000243837 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                      | 05/02/2025 | N/A |    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000245529   | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted   | 05/02/2025   | N/A   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|